



Liwei Zhang
China

Professor of Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University. Associate Director of National Center for Clinical Medicine of Neurological Diseases, Member of Academia Europaea, He has made great contributions in the research and clinical treatment of brainstem tumors as well as in the platform of National Brain Tumor Registry. He has made great efforts and breakthroughs in the basic research of brainstem glioma. For example, he has identified somatic gain-of-function PPM1D mutations of brainstem glioma (Nat Genet. 2014), also identified deep sequencing of CSF ct-DNA to be a reliable technique for detecting tumor specific alterations in brainstem tumors, (Acta Neuropathol. 2018), moreover, he had led a team to identify the integrated genomic and epigenomic landscape of brainstem glioma, (Nat Commun. 2020 ; Nat Cancer. 2022). As the first author (or corresponding author), he has published more 200 scientific research papers in international well-known academic journals.

Topic: Brainstem Glioma Immunotherapy Trial

Diffuse intrinsic pontine glioma (DIPG) harboring H3.3-K27M mutation is a malignant pediatric brain tumor with a 90% mortality rate within two-year of diagnosis. Current therapeutic options for DIPG are limited. Aiming to improve therapeutic outcomes, we herein report the preliminary findings of a phase I trial studying a neoantigen peptide vaccine targeting H3.3-K27M.